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ABSTRACT: Vascular smoothmuscle cells (VSMCs) play critical roles in the stability and tonic regulation of vascular
homeostasis. VSMCs can switch back and forth between highly proliferative synthetic and fully differentiated
contractile phenotypes in response to changes in the vessel environment.Although abnormal phenotypic switching
ofVSMCs is ahallmarkofvasculardisorders suchasatherosclerosis and restenosis after angioplasty, howcontrol of
VSMCphenotypic switching isdysregulated inpathologic conditions remains obscure.We found that inhibition of
canonical transient receptor potential 6 (TRPC6) channels facilitated contractile differentiation of VSMCs through
plasma membrane hyperpolarization. TRPC6-deficient VSMCs exhibited more polarized resting membrane po-
tentials and higher protein kinase B (Akt) activity than wild-type VSMCs in response to TGF-b1 stimulation.
Ischemic stress elicited by oxygen-glucose deprivation suppressed TGF-b1-induced hyperpolarization and VSMC
differentiation, but this effect was abolished by TRPC6 deletion. TRPC6-mediated Ca2+ influx and depolarization
coordinately promoted the interaction of TRPC6 with lipid phosphatase and tensin homolog deleted from chro-
mosome 10 (PTEN), a negative regulator of Akt activation. Given the marked up-regulation of TRPC6 observed in
vascular disorders, our findings suggest that attenuation of TRPC6 channel activity in pathologic VSMCs could be
a rational strategy to maintain vascular quality control by fine-tuning of VSMC phenotypic switching.—
Numaga-Tomita, T., Shimauchi, T., Oda, S., Tanaka, T., Nishiyama, K., Nishimura, A., Birnbaumer, L., Mori, Y.,
Nishida, M. TRPC6 regulates phenotypic switching of vascular smooth muscle cells through plasma membrane
potential-dependent coupling with PTEN. FASEB J. 33, 9785–9796 (2019). www.fasebj.org
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Vascular smooth muscle cells (VSMCs) play important
roles in the tonus regulation of blood vessels (1). To adapt
to increases and decreases of blood flow, blood vessels
need structural flexibility. To achieve this, VSMCs sur-
rounding a monolayer of endothelial cells proliferate to
increase thediameter of bloodvessels. In addition,VSMCs
are important to stabilize nascent capillaries composed
of endothelial cells. To surround endothelial capillaries,
precursors of VSMCs proliferate and migrate to those
capillaries. Thus, VSMCs exhibit dual phenotypes: a syn-
thetic one in which VSMCs are highly mobile and pro-
liferative and a second contractile form in which VSMCs
develop an acto-myosin contraction system and alter their
own tension in response to vasoconstriction or vasodila-
tion (1). VSMCs are capable of switching between syn-
thetic and contractile phenotypes to maintain vessel
homeostasis. However, in pathologic conditions such as
atherosclerosis and pulmonary hypertension, the pheno-
type of VSMCs is fixed in synthetic mode, which makes
blood vessels stiff and reduces their diameter (2, 3). As
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such, suppressing the proliferative activity of synthetic
VSMCs and promoting the transition of synthetic VSMCs
to a contractile phenotype could be potential therapeutic
strategies for VSMC-related vessel diseases such as ath-
erosclerosis, pulmonary hypertension, stroke, and pe-
ripheral artery disease (4). However, the molecular
mechanisms underlying the transition of VSMCs from a
proliferative to contractile phenotype remain obscure.
Canonical transient receptor potential 6 (TRPC6)
protein forms a nonselective cation channel that is acti-
vated by diacylglycerol, which is produced by surface
receptor-coupled PLC activation (5). In blood vessels,
TRPC6 activation upon exposure to a vasoconstrictor,
such as angiotensin II or endothelin, induces membrane
depolarization and Ca2+ influx via voltage-dependent
Ca2+ channels, thus resulting in eventual VSMC con-
traction (6, 7). In contrast, endothelium-stimulating va-
sodilators evoke release of NO or prostaglandin I2,
which leads to activation of protein kinase G (PKG) or
protein kinase A (PKA) in VSMCs, respectively (8–10).
Indeed, the TRPC6 channel possesses a phosphorylation
site for both PKA and PKG. Suppression of TRPC6 by
phosphorylation reportedly inhibits VSMC contraction
to result in vasodilation (7, 11, 12). Although the role of
TRPC6 has been well characterized in acute vessel
function, its role in chronic disorders is still largely un-
known. The only example is idiopathic pulmonary
arterial hypertension (IPAH), for which there is a corre-
lation between a single nucleotide polymorphism in the
TRPC6 gene promoter and patients with IPAH exhibit-
ing significantly elevated expression levels of TRPC6
mRNA and protein (13). Enhanced expression of TRPC6
caused pulmonary arterial smoothmuscle cells (PASMCs)
to switch from a contractile to synthetic phenotype via in-
creased intracellular Ca2+ concentration by up-regulating
store-operatedCa2+ entry (14). However, the effect elicited
by suppression of TRPC6 in VSMC physiology is
unknown.
In this study, primary VSMCs from mouse aorta and
the mesenchymal stem cell line C3H10T1/2 were used to
investigate the effect of TRPC6 deficiency on VSMC phe-
notypic switching. Interestingly, TRPC6 deficiency facili-
tated VSMC differentiation potentially via the regulation
of membrane potential. Indeed, TRPC6-deficient VSMCs
exhibitedmore hyperpolarizedmembrane potentials than
wild-type cells. Moreover, deletion of TRPC6 increased
TGF-b-induced protein kinase B (Akt) activation by sup-
pressing the activation of lipid phosphatase, as well as
phosphatase and tensin homolog deleted from chromo-
some 10 (PTEN). In synthetic VSMCs, TRPC6 interacted
with PTEN and inhibited the production of phosphati-
dylinositol 3,4.5-trisphosphate [PI(3,4,5)P3], leading to at-
tenuation of Akt signaling.
MATERIALS AND METHODS
Cell culture
Primary VSMCswere isolated frommouse aorta at 5 wk of age
as previously described (15). All protocols using mice were
reviewed and approved by ethics committees at the National
Institutes of Natural Sciences or the Animal Care and Use
Committee at Kyushu University, and were performed
according to institutional guidelines concerning the care and
handling of experimental animals. C3H10T1/2 cells were
obtained from Riken BioResource Center (Tsukuba, Ibaraki,
Japan). Cells were cultured in Basal Medium Eagle (BME;
Thermo Fisher Scientific, Waltham, MA, USA) supplemented
with 10% fetal bovine serum (FBS) and 13 penicillin/
streptomycin mixture (Nacalai, Kyoto, Japan). For induction
of VSMCdifferentiation, cells were serum-starved for 24 h then
stimulated with recombinant human TGF-b1 (5 ng/ml;
PeproTech, Rocky Hill, NJ, USA) in BME for the indicated
times. For oxygen-glucose deprivation (OGD), cells were cul-
tured in FBS-free DMEM without glucose (Wako, Osaka, Ja-
pan) and incubated in a multigas incubator (PHC, Tokyo,
Japan) set at 1%O2and 5%CO2 for 24h.After 24 hofOGD, cells
were cultured in BME supplementedwith either 2% FBS, 2 ng/
ml platelet-derived growth factor (PDGF; PeproTech), and
2 ng/ml fibroblast growth factor 2 (PeproTech), or 5 ng/ml
TGF-b1 for24h inanormalCO2 incubator. Isolationandprimary
culture of mouse VSMCs were as previously described (15).
Small interfering RNA transfection
C3H10T1/2 cells were plated 1 d before small interfering RNA
(siRNA) transfection. siRNAs for mouse TRPC6 and negative
control were purchased from Thermo Fisher Scientific (Stealth
RNAi MSS212126 and siRNA Negative Control, Med GC; Wal-
tham, MA, USA). Transfection of siRNAs was carried out using
Lipofectamine RNAiMAX (Thermo Fisher Scientific) at a con-
centration of 20 nMaccording to themanufacturer’s instructions.
Cells were serum-starved and stimulatedwith TGF-b1 72 h after
siRNA transfection.
Immunocytochemistry
Cells seeded onto 12-mm round coverslips were fixed with 4%
paraformaldehyde in PBS, permeabilizedwith 0.5%TritonX-100
in PBS, and then stained with primary anti–a-smooth muscle
actin (a-SMA; MilliporeSigma, Burlington, MA, USA) or anti-
smooth muscle 22 a (SM22a) (Abcam, Cambridge, United
Kingdom) antibodies and secondary Alexa594-conjugated
anti-rabbit IgG (Thermo Fisher Scientific). Coverslips were
mounted onto slide glasses with Prolong Diamond Antifade
Mountant with DAPI (Thermo Fisher Scientific). Fluorescence
images were acquired using a fluorescence microscope with
3100 objective (BX-Z710; Keyence, Osaka, Japan). Combinations
of either a 565-nm excitation filter and 535–675-nm band-pass
filter for emission or a 400-nm excitation filter and 410–510-nm
band-pass filter for emission were utilized for imaging of
Alexa594 or DAPI, respectively. Mean fluorescence intensity/
pixel of each cell (at least 30 cells/image) was analyzed with
ImageJ software (National Institutes of Health, Bethesda, MD,
USA).
Measurement of membrane potential
Cells were loaded with 2 mM DiBAC4 (3) (Thermo Fisher Sci-
entific) containing HEPES-buffered saline solution [HBSS;
140 mM NaCl, 5.6 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
10 mM glucose, and 10 mM HEPES (pH 7.4 adjusted with
NaOH)] at 37°C for 30 min. Fluorescence of DiBAC4 (3) was
measured at an excitation wavelength of 488 nm with a fluo-
rescence microscope with 320 objectives (BX-Z710). Mean
fluorescence intensity/pixel of each cell (at least 100 cells/
image) was analyzed with ImageJ software.
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Western blotting
For membrane fractionation, cells were lysed by sonication
(Waken Btech, Kyoto, Japan) in hypotonic lysis buffer containing
20 mM Tris-HCl (pH 7.4), 10 mM EDTA, 5 mM EGTA, and pro-
teinase inhibitor cocktail (Nacalai). Membrane fractions were pre-
cipitated by ultracentrifugation at 40,000 g at 4°C for 60 min. The
precipitate was dissolved in hypotonic lysis buffer supplemented
with 0.1% SDS, 0.5% sodium deoxycholate, and 1% NP-40. For
westernblotofAkt andSM22a, cellswere lysed in1%TritonX-100
lysisbuffer containing20mMTris-HCl (pH7.8), 140mMNaCl, 1%
Triton X-100, 2 mM EDTA, 10% glycerol, and Halt’s phosphatase
and protease inhibitor cocktail (Thermo Fisher Scientific). For
western blotting, samples were fractionated by SDS-PAGE and
then transferred onto PVDF membranes (Merck, Darmstadt,
Germany). Proteins of interest were detected with the indicated
antibodies. After incubationwith secondary antibody, bandswere
visualized with Western Lightning Plus ECL (PerkinElmer, Wal-
tham,MA,USA). Imageswere capturedwith an ImageQuantLAS
4000 and quantified using ImageQuant TCL software (GE
HealthcareLife Science,Chicago, IL,USA).Anti-TRPC6 (Alomone
labs, Jerusalem, Israel), anti-glyceraldehyde 3-phosphate de-
hydrogenase (Santa Cruz Biotechnology, Dallas, TX, USA), anti-
SM22a, anti-phospho-Akt (Ser473), anti-Akt, and anti-PTEN (Cell
Signaling Technology, Danvers, MA, USA) antibodies were used
at 1:2000 dilutions.
Electrophysiology
1-Oleoyl-2-acetyl-sn glycerol (OAG)-induced currents were
measured using the whole-cell patch-clamp technique with an
EPC-10 patch-clamp amplifier (HEKA Elektronik, Lambrecht/
Pfalz, Germany). Patch electrodes with a resistance of 3–4 MV
(when filled with internal solution) were made from 1.5-mm
borosilicate glass capillaries (Sutter Instrument, Novato, CA,
USA). Voltage-clamp experiments were performed at a holding
potential of 240 mV, with recordings sampled at 2.0 kHz and
filtered at 2.9 kHz. To analyze I–V relationships, ramp pulses
from2100 to 100mV over 250mswere applied every 30 s. Cells
were allowed to settle in the perfusion chamber in external so-
lution containing140mMNaCl, 5.6mMKCl, 1mMMgCl2, 2mM
CaCl2, 10 mMHEPES, and 10 mM glucose (pH 7.4). The pipette
solution contained 120 mM CsOH, 120 mM aspartate, 20 mM
CsCl, 2mMMgCl2, 5mMEGTA, 1.5mMCaCl2, 10mMHEPES,
2 mM ATP-Na2, 0.1 mM GTP, and 10 mM glucose (pH 7.2, ad-
justed with Tris base). Cells were superfused with standard ex-
ternal solution in the presence or absence ofOAGapplied focally
using a Y-tube perfusion system. Cells were stimulated with
TGF-b1 for24hand recorded3hafterplatingonglass coverslips.
Pyrazole (Pyr, 10 mM) 2 was focally applied to cells beginning 3
min before OAG stimulation.
Boyden chamber cell migration assay
Cell migration was measured with a Boyden chamber as-
say. Mouse VSMCs were serum-starved overnight and seeded
into the upper chamber of Transwell culture inserts (8-mm
prepolycarbonate membrane; Corning, Corning, NY, USA).
PDGF-BB (50 ng/ml, human recombinant; R&D Systems, Min-
neapolis, MN, USA) was added to the bottom chambers. Six
hours after PDGF treatment, nonmigrating cells on the upper
surface of the filter were removed, and migrated cells on the
lower surface of the filter were permeabilized and stained with
hematoxylin (MilliporeSigma). Cells were observed by inverted
microscopy with 310 objective lens and counted. Four fields/
Transwell insert were analyzed. Averaged data from 3 in-
dependent experiments were calculated.
Cell proliferation assay
Mouse VSMCs were seeded into 12-well plates (1 3 104 cells/
well).After serumstarvationovernight, cellswere treatedwith50
ng/ml PDGF-BB. Cells were trypsinized and counted with a
hemocytometer every 24 h until 7 d after treatment.
Duolink proximity ligation assay
MouseVSMCswere fixedwith 3%v/vglyoxal (MilliporeSigma)
solution for 30 min on ice and another 30 min at room tempera-
ture. Glyoxal was quenched with 100 mM NH4Cl for 20 min at
room temperature. Cells were permeabilized with Tris-buffered
saline solution (pH 7.4) containing 0.5% Triton X-100 for 10 min
and then blocked with Tris-buffered saline solution containing
0.1% Triton X-100 and 1% bovine serum albumin for 1 h at room
temperature. Cells were incubated with anti-TRPC6 antibody
and anti-PTEN antibody (A2B1; Santa Cruz Biotechnology) at
4°C overnight. Incubation with proximity ligation assay (PLA)
probes and detection were carried out according to the manu-
facturer’s instructions (Duolink In Situ Red Starter Kit Mouse/
Rabbit;MilliporeSigma). Imageswere acquired by confocal laser
microscopywith a360 objective lens (Nikon, Tokyo, Japan). The
number of PLA signals in single cells was analyzed with ImageJ
software.
Measurement of changes in [Ca2+]i
Measurement of changes in [Ca2+]i was carried out as previously
described (16). Briefly, cells were loaded with the fluorescent
Ca2+ indicator Fura-2 (Dojindo, Kumamoto, Japan) and fluores-
cence images recorded from cells incubated in HBSS were ana-
lyzed with a video image analysis system (Aqua Cosmos;
Hamamatsu Photonics, Hamamatsu, Japan). Hyperforin was
purchased fromMilliporeSigma.
Statistics
Results are presented as means 6 SEM of 3 or 5 independent
experiments using primary mouse VSMCs or C3H10T1/2 cells,
respectively. Statistical significance was determined using an
unpaired t test for 2-group comparisons, or 2-wayANOVAwith
Sidak’s post hoc test for comparison of 3 or more groups. Signif-
icance was considered at a value of P, 0.05.
RESULTS
Suppression of TRPC6 promoted
VSMC differentiation
We first analyzed the involvement of TRPC6 in
VSMC phenotypic switching using primary murine
VSMCs isolated from either wild type [TRPC6(+/+)] or
TRPC6knockout [TRPC6(2/2)]mice.TRPC6(2/2) cells
exhibited increased a-SMA immunofluorescence com-
pared with TRPC6(+/+) cells in response to serum with-
drawal (Fig. 1A), indicating differentiation of VSMCswas
facilitated in TRPC6(2/2) cells. We next analyzed prop-
erties of migration and proliferation of VSMCs to analyze
the effect of TRPC6 deficiency on the synthetic phenotype
of VSMCs. PDGF is the major cytokine for mural cell re-
cruitment to capillaries (17). Upon PDGF stimulation,
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neither cell migration nor proliferation were affected by
TRPC6 deletion (Fig. 1B, C). Loss of TRPC6 protein ex-
pressionwas confirmedbywesternblot analysis (Fig. 1D).
Hyperforin, a TRPC6 channel activator (18), increased
intracellular Ca2+ concentration ([Ca2+]i) in TRPC6(+/+)
VSMCs, but this effect was significantly reduced in
TRPC6(2/2) VSMCs (Fig. 1E). The remaining [Ca2+]i
increase in TRPC6(2/2) cells might be caused by the re-
lease of Ca2+ from intracellular organelles such as mito-
chondria (19). These data suggest that TRPC6 deficiency
does not promote or compromise the proliferative or mi-
gratory activities of synthetic VSMCs.
TRPC6 deficiency polarized
membrane potential
It has been recognized that more quiescent and fully dif-
ferentiated cells exhibit relatively polarized membrane
potentials ranging from 250 to 290 mV, whereas more
plastic stem cells exhibit less polarized membrane poten-
tials averaging between 210 and 240 mV (20). TRPC6 is
reportedly involved in the regulation of membrane po-
tential in VSMCs and bone marrow stromal cells (21, 22).
Therefore, we next assessed the membrane potential in
synthetic and contractile VSMCs in the presence or ab-
sence of TRPC6 gene expression. Cells loaded with the
slow kinetic membrane potential dye DiBAC4 (3) were
evaluated for florescence intensity (23). TGF-b1 treatment
significantly reduced DiBAC4 (3) fluorescence in VSMCs,
suggesting that the induction of switching to a contractile
phenotype elicited by exposure to TGF-b1 caused hyper-
polarization of resting membrane potential compared
with synthetic cells (Fig. 2A). In contrast, deletion of
TRPC6 hardly affected resting membrane potential in
synthetic VSMCs. Moreover, contractile TRPC6(2/2)
cells exhibitedmore hyperpolarizedmembrane potentials
than contractile TRPC6(+/+) cells (Fig. 2A). Simulta-
neously, TGF-b1 stimulation increased SM22a expression
to a higher level in TRPC6(2/2) cells compared with
TRPC6(+/+) cells (Fig. 2B). Thesedata suggest that TRPC6
functions to maintain resting membrane potential at a
relatively depolarized state and, moreover, there is a cor-
relation between membrane potential and VSMC pheno-
typic switching in which TRPC6 plays a key role.
TRPC6 negatively regulated switching to a
contractile phenotype by suppressing
Akt activation
We next investigated whether VSMC differentiation
affected TRPC6 channel activity. As a VSMC differen-
tiation model, we used the C3H10T1/2 mesenchymal
stem cell line, a well-defined VSMC differentiation
model. Stimulation with TGF-b has been shown to
differentiate C3H10T1/2 cells into smooth muscle cells
(24–26). To reveal the relationship between VSMC
Figure 1. TRPC6 deletion facilitated VSMC differentiation but not proliferation. A) Representative immunostaining images of
a-SMA in VSMCs 3 d after serum withdrawal. Scale bars, 20 mm. Nuclei were visualized with DAPI. Quantification of a-SMA
fluorescence intensity (right, n = 3). B, C) Quantification of PDGF-induced cell migration (B, n = 3) and proliferation (C, n = 3)
of C6(+/+) (closed circle) and C6(2/2) (open square) VSMCs. Cells were stimulated with PDGF (2 ng/ml) for 12 h in Boyden
chamber assays. D) Expression of TRPC6 protein in mouse aortic VSMCs. Representative blots from 3 independent experiments
are shown. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. E) Hyperforin-induced Ca2+ responses in C6(+/+) and C6(2/2)
VSMCs. Cells were stimulated with hyperforin (10 mM). Averaged peak Ca2+ increases are shown [right, n = 40 for C6(+/+), n = 42,
n = 54 for C6(2/2)]. Data represent means 6 SEM. **P , 0.01, ***P , 0.001.
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differentiation and TRPC6 activity, we analyzed
the effect of TGF-b1 on TRPC6 channel activity in
C3H10T1/2 cells using whole-cell patch-clamp meth-
odology. Endogenous TRPC6 channel-dependent cur-
rent was induced by stimulating C3H10T1/2 cells with
OAG, a membrane permeable analog of 1,2-diacyl-
glycerol (Fig. 3A, B). OAG-induced current was signifi-
cantly suppressed by treatment with Pyr2 (also known
as BTP2), a broad inhibitor of TRPC channels (16). TGF-
b1-treated cells exhibited a marked reduction of
OAG-induced current, suggesting that VSMC-like dif-
ferentiated cells have less TRPC6 activity than pro-
liferative cells (Fig. 3A, B). In addition, treatment
with TGF-b1 hardly reduced TRPC6 mRNA levels (Fig.
3C), suggesting that TGF-b1 induces differentiation
of C3H10T1/2 cells concomitant with suppression of
TRPC6 channel activity but without TRPC6 down-
regulation. siRNA transfection significantly suppressed
TRPC6 expression at bothmRNA and protein levels (Fig.
3C, D). Next, we investigated how TRPC6 knockdown
affected VSMC differentiation of C3H10T1/2 cells. Stim-
ulation with TGF-b1 increased the protein abundances of
differentiation markers a-SMA and SM22a, indicated by
both immunofluorescence andwestern blot analyses (Fig.
3E, H). siRNA-knockdown of TRPC6 had no impact
on basal levels of a-SMA or SM22a proteins, although
it markedly increased TGF-b1-stimulated inductions of
those markers (Fig. 3E, H). In contrast, overexpression of
TRPC6 almost completely suppressed a-SMA induction
in TGF-b1-stimulated C3H10T1/2 cells (Fig. 3F). These
data suggest that TRPC6 negatively regulates the in-
duction of VSMC differentiation. Differentiation of
C3H10T1/2 cells into VSMCs is reportedly regulated by
Akt (27). We found that knockdown of TRPC6 signifi-
cantly increased TGF-b1-induced Akt phosphorylation at
Ser473 (Fig. 3G). To confirm the involvement of Akt acti-
vation in facilitatingVSMCdifferentiation throughTRPC6
down-regulation, cells were treated with LY-294002, a
PI3K inhibitor. LY-294002 suppressed the increase of
SM22a protein induced by TGF-b1 at the same level in
both control and TRPC6-knockdown cells (Fig. 3H). These
data suggest that TRPC6 activity is inversely correlated
with VSMC differentiation via regulation of the Akt sig-
naling pathway.
Ischemic conditions suppressed VSMC
differentiation in a TRPC6-dependent manner
We next examined whether ischemic conditions im-
pacted TGF-b1-induced differentiation of C3H10T1/2
cells, as ischemic-reperfusion causes an aberrant in-
crease of reactive oxygen species—the most important
driver of vessel disease (28). Exposure to OGD signifi-
cantly suppressed TGF-b1-induced increases of SM22a
expression in siControl-transfected C3H10T1/2 cells
(Fig. 4A). However, strikingly, knockdown of TRPC6
increased SM22a expression even in OGD-treated
cells (Fig. 4A). TRPC6(2/2) primary VSMCs exhibited
Figure 2. TRPC6 deletion hyperpolarized rest-
ing membrane potential in VSMCs. A) Repre-
sentative images of DiBAC4 (3) fluorescence in
in C6(+/+) and C6(2/2)VSMCs treated with
TGF-b1. Cells were treated with TGF-b1 (5 ng/
ml) for 48 h after 24-h serum starvation.
Control cells were cultured in the presence of
20% FBS. Scale bars, 50 mm. Averaged fluores-
cence intensity/pixel was quantitated (right,
n = 4). B) Representative immunostaining
images of SM22a in VSMCs stimulated with
TGF-b1 (5 ng/ml) for 48 h. Scale bars, 50 mm.
Nuclei were visualized with DAPI. Average
fluorescence intensities/pixel were quantitated
(right, n = 3). Data represent means 6 SEM.
*P , 0.05, **P , 0.01.
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Figure 3. TRPC6 deletion facilitated VSMC differentiation by up-regulating the Akt signaling pathway in C3H10T1/2 cells. A, B)
OAG-induced cation current in C3H10T1/2 cells. I–V relationship (A) and averaged maximum current density (B) 2 min after
OAG (10 mM) stimulation (n = 6 for control cells, n = 5 for TGF-b1-treated cells, n = 5 for Pyr2-treated cells). Cells were treated
with TGF-b1 (5 ng/ml) for 48 h and plated on coverslips. Pyr2 (10 mM) was applied focally 3 min before OAG stimulation and
throughout the recording. C) mRNA expression of TRPC6 in siTRPC6-transfected C3H10T1/2 cells (n = 5). Cells were treated
with TGF-b1 for 24 h. D) Expression of TRPC6 protein in siRNA-transfected C3H10T1/2 cells normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) protein (n = 5). E) Immunofluorescence of a-SMA in TGF-b1-stimulated C3H10T1/2 cells
(n = 5). Scale bars, 20 mm. Nuclei were visualized with DAPI. F) Immunofluorescence of a-SMA in C3H10T1/2 cells stably
expressing 33 Flag-tagged TRPC6 (n = 5). Scale bars, 20 mm. Nuclei were visualized with DAPI. G) Akt phosphorylation in TGF-
b1-stimulated C3H10T1/2 cells transfected with siTRPC6. pAkt, phosphorylated Akt. Data were normalized to untreated
siControl-transfected cells (n = 5). H) SM22a expression in TGF-b1-stimulated C3H10T1/2 cells treated with LY-294002 (50 mM).
Cells were pretreated with LY-294002 for 30 min before TGF-b1 treatment (24 h). Data were normalized to untreated siControl-
transfected cells (n = 5). Data represent means 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001.
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increased a-SMA immunofluorescence compared with
TRPC6(+/+) cells in response to TGF-b1 stimulation in
normoxic conditions (Fig. 4B). Although OGD signifi-
cantly inhibited TGF-b1-induced VSMC differentiation
of TRPC6(+/+) cells, TRPC6 deficiency abolished the
suppression of VSMCdifferentiation elicited by OGD of
primary VSMCs (Fig. 4B). These results suggest that
down-regulation of TRPC6 during switching to the
contractile phenotype is abrogated under pathologic
conditions.
TRPC6 interacts with PTEN and inhibits the Akt
signaling pathway
In our search for the downstream signaling machinery
linking TRPC6 activity and Akt activation, we focused on
the PTEN molecule. As PTEN is a lipid phosphatase, es-
pecially for PI(3,4,5)P3, it is a common negative regulator
of the PI3K/Akt signaling pathway. Previous reports
suggest that TRPC6 interacts with PTEN in endothelial
cells and VSMCs, and this interaction is important for cell
surface expression of TRPC6 (29, 30). Based on these ob-
servations, we analyzed the interaction of TRPC6 and
PTEN during phenotypic switching under either physio-
logic or pathophysiological conditions. To analyze the
interaction between endogenous proteins, we utilized a
PLA. PLA results demonstrated that native TRPC6 inter-
acted with PTEN in synthetic VSMCs but was signifi-
cantly suppressed by TGF-b1 treatment (Fig. 5A, B).
OGD-treated proliferative VSMCs showed significantly
increased TRPC6-PTEN interactions compared with cells
innormoxic conditions (Fig. 5A,B).Moreover, a significant
amount of TRPC6-PTEN interactions was retained in
OGD-treated cells after TGF-b1 stimulation (Fig. 5A, B).
Consistent with these data, TRPC6(2/2) VSMCs exhibi-
ted increased Akt activity compared with TRPC6(+/+)
cells in response to TGF-b1 stimulation (Fig. 5C, D). Fur-
thermore, Akt activation was increased in OGD-treated
TRPC6(2/2) cells upon TGF-b1 stimulation comparable
to normoxic cells (Fig. 5C, D). These data suggest that
TRPC6 negatively regulated VSMC differentiation by
suppressing Akt activity in close association with PTEN.
Next,we analyzed the effect ofOGDon restingmembrane
potential. OGD exposure prior to TGF-b1 stimulation
inhibited the negative shift of resting membrane potential
inTRPC6(+/+) cells (Fig. 5E). In contrast, TGF-b1-induced
Figure 4. Ischemic conditions suppressed VSMC differentiation in a TRPC6-dependent manner. A) SM22a expression in TGF-b1-
stimulated C3H10T1/2 cells after 24-h exposure to OGD or normoxic (N) conditions. Increases are shown relative to untreated
siControl-transfected cells in N conditions (n = 5). Samples were loaded on the same gel. B) Representative images (upper) and
quantitation (lower) of immunofluorescence of a-SMA in VSMCs stimulated with TGF-b1 (n = 3). Scale bars, 20 mm. Cells were
cultured in OGD condition for 24 h followed by stimulation with TGF-b1 (5 ng/ml) in normal culture medium and O2 level for
48 h. Nuclei were visualized with DAPI. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Data represent means 6 SEM. **P
, 0.01, ***P , 0.001.
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hyperpolarizationofmembranepotential inTRPC6(2/2)
cells was insensitive to OGD preconditioning, indicating
that the ischemic condition abrogated the polarization of
resting membrane potential during VSMC differentiation
by affecting TRPC6 activity.
Depolarization of membrane potential
inhibited VSMC differentiation by
maintaining PTEN membrane localization
To analyze the importance of TRPC6-dependent changes
of resting membrane potential in VSMC differentiation,
C3H10T1/2 cellswere treatedwithTGF-b1 in thepresence
of additional extracellular KCl. Supplementation of KCl
suppressed VSMC differentiation in a dose-dependent
manner (Fig. 6A), suggesting that membrane depolariza-
tion inhibited TGF-b1-induced VSMC differentiation.
PTEN possesses a C2 domain that is critical for its activa-
tion, as it brings PTEN to the plasma membrane. The C2
domain binds to anionic phospholipids such as phospha-
tidylserine (PS) and phosphatidylinositol in a Ca2+-
dependent manner. Recent findings indicate that mem-
brane potential affects the distribution of PS in the
plasma membrane (31). Therefore, we analyzed the ef-
fect of membrane depolarization on localization of
PTEN to the plasma membrane by supplementing cells
with additional extracellular KCl. The abundance of
PTEN in the membrane fraction of C3H10T1/2 cells
was significantly reduced by 48-h TGF-b1 stimulation
(Fig. 6B). In contrast, therewas no effect of excessKCl on
the association of PTEN to the membrane in control
cells. However, excess KCl suppressed the TGF-b1-in-
duced reduction of membrane-bound PTEN in differ-
entiating cells (Fig. 6B), suggesting that membrane
hyperpolarization in differentiating VSMCs is critical for
inhibiting PTEN activation by keeping it away from
the plasma membrane. To confirm the involvement
of TRPC6 in PTEN membrane association, we ana-
lyzed relative quantities of membrane-bound PTEN in
C3H10T1/2 cells transfected with siTRPC6. In this ex-
periment, cellswere treatedwith TGF-b1 for 12 h, during
which PTEN was still well-associated in the membrane
Figure 5. Ischemic conditions inhibited Akt activation via up-regulation of TRPC6-PTEN interaction and membrane
depolarization in VSMCs. A) TRPC6-PTEN interaction in mouse VSMCs stimulated with TGF-b1 following exposure to OGD
or normoxic (N) conditions as analyzed by Duolink PLA. Scale bars, 50 mm. Nuclei were visualized with DAPI. B) Quantitation of
PLA signals in A (n = 18 cells). C) TGF-b1-induced Akt phosphorylation in mouse primary VSMCs isolated from C6(+/+) or
C6(2/2) mice. Samples were loaded on the same gel. D) Quantification of Akt phosphorylation (n = 3 replicates); increases are
shown relative to untreated C6(+/+) cells in N conditions. E) Averaged DiBAC4 (3) fluorescence in VSMCs stimulated with TGF-
b1 after exposure to OGD or N conditions (n = 3 replicates). Cells were cultured under OGD or N conditions for 24 h prior to
TGF-b1 stimulation (5 ng/ml for 24 h). pAkt, phosphorylated Akt. Data represent means 6 SEM. *P , 0.05, **P , 0.01, ***P ,
0.001.
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Figure 6. The mechanism by which TRPC6 contributes to VSMC differentiation. A) Immunofluorescence imaging of SM22a in TGF-b1-
stimulated C3H10T1/2 cells in the presence of additional extracellular KCl. Cells were treated with TGF-b1 and indicated concentrations of
KCl for 48 h. Representative images (left) and quantification of SM22a-positive cells (right) are shown (n = 5). Scale bars, 50 mm. Nuclei
were visualized with DAPI. B) Membrane association of PTEN in TGF-b1-stimulated C3H10T1/2 cells in the presence or absence of
additional extracellular KCl (30 mM). Cells were treated with TGF-b1 (5 ng/ml) and KCl for 48 h. Densitometric analysis of membrane-
associated PTEN protein normalized to total PTEN protein (right, n = 5); increases are shown relative to untreated control cells. C) PTEN
membrane association in siRNA-transfected C3H10T1/2 cells. Cells were stimulated with TGF-b1 (5 ng/ml) for 12 h. Increases are shown
relative to untreated siControl-transfected cells. D) TRPC6 permeates Na+ and Ca2+ in proliferating VSMCs, which causes a slight
depolarization of membrane potential that affects anionic phospholipid distribution in the inner leaflet of the plasma membrane. The C2
domain of PTEN binds to Ca2+ in the proximal region of themouth of the TRPC6 channel and brings PTEN close to the substrate PI(3,4,5)
P3 in the plasma membrane via interaction with clustered anionic phospholipids such as PS. TGF-b1 stimulation suppressed TRPC6
channel activity, which hyperpolarized membrane potential and inhibited Ca2+ influx, resulting in dissociation of PTEN from the plasma
membrane and accumulation of PI(3,4,5)P3 that induces Akt activation. *P , 0.05, **P , 0.01, ***P , 0.001.
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compartment in siControl-transfected cells (Fig. 6C). In
contrast, TRPC6 knockdown significantly accelerated
membrane dissociation of PTEN after 12-h TGF-b1
stimulation (Fig. 6C). These data indicate that TRPC6 is
important for both the membrane association of PTEN
and membrane hyperpolarization, which involves the
suppression of TRPC6 to trigger dissociation of PTEN
from the membrane, thereby inducing VSMC differen-
tiation marker expression (Fig. 6D).
DISCUSSION
In this study, we found that inhibition of TRPC6 channel
activity facilitated VSMC differentiation via the hyperpo-
larization of membrane potential. Thus, TRPC6 functions
tonegatively regulate ormaintain the synthetic phenotype
of VSMCs. In synthetic VSMCs, PTEN can be activated at
the plasma membrane through a functional and physical
interaction with TRPC6, whereby PTEN reduces accu-
mulation of PI(3,4,5)P3. TGF-b1 stimulation suppressed
TRPC6 activation, which caused release of PTEN from the
plasma membrane, PI(3,4,5)P3 accumulation, and activa-
tion of Akt, a critical regulator of the switch to contractile
phenotype of VSMCs (Fig. 6D).
TRPC6 is adisease geneof IPAH. Inpatientswith IPAH
(32), TRPC6 expression is quite high compared with nor-
mal subjects (13). This up-regulation of TRPC6 is likely
responsible for the increase of [Ca2+]i observed inPASMCs
(14). Indeed, increased [Ca2+]i is the key determinant for
transition from a contractile to synthetic phenotype of
PASMCs (14, 33), and TRPC6 is believed to maintain the
synthetic phenotype of PASMCs through regulation of
Ca2+ influx. In this study, we also demonstrated that
contractileVSMCshave lessTRPC6activity than synthetic
cells. As a Ca2+ channel, this is consistent with data de-
scribingPASMCs. The importance ofCa2+ influx inVSMC
phenotypic switching has been also demonstrated by
research investigating other Ca2+-permeable channels,
such as store-operated Ca2+ channels (SOCCs) composed
of stromal interaction molecule 1 and Orai calcium
release-activated calcium modulator 1 proteins (34–36).
Several studies have reported increased SOCC compo-
nents in pathologic conditions, which caused aberrant
proliferation of SMCs in neointima formation or pulmo-
nary hypertension (14, 33). These data suggest that SOCCs
are more important for maintaining the synthetic pheno-
type rather than the contractile 1. It has been recognized
that VSMCs are heterogeneous among and within differ-
ent tissues (37). Therefore, there is a concernaboutwhether
the importance of TRPC6 in phenotypic switching is spe-
cific for arterial smooth muscle cells. In this study, we
utilized the mesenchymal stem cell line C3H10T1/2 and
demonstrated that TGF-b1-inducedVSMCdifferentiation
of those cells was also facilitated by TRPC6 suppression,
suggesting that TRPC6-mediated maintenance of the
syntheticphenotype is auniversalmechanismof allVSMC
lineages. Beyond the aspect of Ca2+ signaling, we were
interested in the functionofTRPC6as anonselective cation
channel, and demonstrated that it depolarizes membrane
potential to activate voltage-gated Ca2+ channels, thus
evoking the sustained Ca2+ influx required for activation
of Ca2+-dependent transcription factors or vascular tonus
regulation in cardiomyocytes or VSMCs, respectively (7,
23). Therefore, we investigated the effect of TRPC6 de-
ficiency on membrane potential instead of Ca2+ signaling
andshowed that contractileVSMCshaveamorepolarized
membrane potential than synthetic cells—a feature de-
pendent on TRPC6. Contractile VSMCs are quiescent and
minimally proliferative. As such, it is interesting that fully
differentiated VSMCs have relatively polarized mem-
brane potentials, whereas nondifferentiating stem cells
exhibit depolarized membrane potentials (20). Therefore,
TRPC6 might have universally important roles in the
regulation of membrane potential in other cellular sys-
tems. However, current conducted by TRPC6 is not large.
Thus, it is difficult to believe that TRPC6 directly regulates
membrane potential through its channel activity. As such,
how TRPC6 contributes to the regulation of membrane
potential remains elusive and will be an important ques-
tion for our future work.
PTEN acts as a major negative regulator of Akt by
reducing PI(3,4,5)P3. A few reports have demonstrated
the interaction between TRPC6 and PTEN (29, 30);
moreover, they demonstrated the importance of PTEN
for surface expression of TRPC6. In this study, we
demonstrated that TRPC6 could also regulate PTEN
activity through a physical interaction. Indeed, this is a
very reasonable coupling, as it has been revealed that
TRPC6 channel activity requires phosphatidylinositol
4,5-bisphosphate for its full activation (38). Close as-
sociation with PTEN can increase the local concentra-
tion of phosphatidylinositol 4,5-bisphosphate around
TRPC6. Furthermore, Ca2+ influx mediated by TRPC6
can supply Ca2+ to the C2 domain of PTEN to main-
tain its membrane association. In this scenario, de-
polarization of membrane potential by TRPC6 is quite
important. It has been reported that membrane de-
polarization induces cluster formation of anionic
phospholipids such as PS and phosphatidylinositols
(31). As membrane association of the C2 domain de-
pends on the binding of Ca2+ and an anionic phos-
pholipid (39), TRPC6-mediated Ca2+ influx may
directly affect membrane recruitment of PTEN through
its C2 domain (Fig. 6D). In addition, membrane de-
polarization also reportedly induces clustering of PS
on the inner leaflet of the plasmamembrane (31). Thus,
TRPC6-mediated cation influx plays 2 roles for PTEN
membrane recruitment: Na+/Ca2+ influx-mediated
membrane depolarization induces clustering of
PS and other anionic phospholipids, and Ca2+
influx-dependent binding of the C2 domain with an
anionic phospholipid leads to recruitment of PTENto the
plasma membrane (Fig. 6D). In this study, we showed
that membrane depolarization by the addition of excess
KCl in the extracellular medium prevented TGF-b1-in-
duced PTEN dissociation from the membrane. This re-
sult supports the idea that resting membrane potential
affects the distribution of anionic phospholipids in in-
ner leaflet of the plasma membrane. This membrane
potential-dependent regulation of phospholipid distri-
bution would be important for C2 domain-dependent
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recruitment of PTEN to the plasma membrane. We pre-
viously demonstrated that TRPC3 is a closely related
isoform of TRPC6 that couples with PKCb to regulate its
membrane translocation in a C2 domain-dependent
manner (40). As the relationship between the distribu-
tion of anionic phospholipid and membrane potential is
mostly unknown, this perspectivemight be an important
clue for identifying the importance of membrane po-
tential, especially in nonexcitable cells.
To analyze the possibility that TRPC6-mediatedVSMC
phenotype regulation plays a role in pathologic VSMCs,
we utilized ischemic preconditioning by culturing cells in
OGD condition before TGF-b1 treatment as an in vitro
diseasemodel.OGD isoneof the simplestways to increase
reactive oxygen species, themost critical disease driver, in
native systems. OGD treatment abolished TGF-b1-
induced suppression of the TRPC6-PTEN interaction
in VSMCs, thus forming a part of the underlying
mechanism for inhibition ofVSMCdifferentiation byOGD
treatment. Therefore, synthetic VSMCs exposed to ische-
mic conditions lose the ability to differentiate into a
VSMC-like phenotype in response to TGF-b, in part due to
a lack of ability to inhibit TRPC6 channel activity and
maintain the interaction between TRPC6 and PTEN.
Therefore, loss of TRPC6 channel activity makes VSMCs
more switchable to the contractile phenotype even under
ischemic conditions. The search for a mechanism of in-
activationofTRPC6 in contractileVSMCsand its inhibition
by OGD is currently ongoing. However, the fact that sup-
pression of TRPC6 can circumvent the effect of ischemia on
VSMCdifferentiation implies TRPC6 is a novel drug target
for atherosclerosis and diabetes in which proliferative
VSMCs underlie poor prognostics (41).
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